K

Kyverna Therapeutics
D

KYTX

9.71000
USD
-1.52
(-13.54%)
مغلق
حجم التداول
53,124
الربح لكل سهم
-3
العائد الربحي
-
P/E
-3
حجم السوق
587,749,145
المقالات
المزيد

العنوان: Kyverna Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.